Takeda inks sweet $1.2B+ deal with Kumquat for immuno-oncology program: Takeda has offered Kumquat Biosciences the chance to make more than $1.2 billion in a new exclusive pact that centres around an immune-oncology small molecule inhibitor. After running phase 1 trial activities Kumquat can grant Takeda global licensing rights to develop and commercialise the asset. Big Pharma Takeda will then take responsibility for all development and commercialisation activities following phase 1. Subsequently a selected program can be developed as a monotherapy, combo therapy or both. Kumquat is set to make up to $130 million in near-term payments, with additional chance to grab $1.2 billion in future clinical, regulatory and commercial milestones. Share your thoughts on the collaboration: #takeda #oncology #kumquat #biosciences #licensingdeals
G&E Partners’ Post
More Relevant Posts
-
More moving and 'shaking' in the #OncologyDevelopment space: So soon after Merck inked their own deal, the MA biotech C4 Therapeutics, Inc. signs another with Merck KGaA, Darmstadt, Germany to seek out two #ProteinDegraders. #Oncology #MerckKGaA #Biotech #Innovation #Licensing #Pharma #Healthcare
C4 brings the Mercks to the yard, with Merck KGaA paying $16M to join protein degrader hunt
fiercebiotech.com
To view or add a comment, sign in
-
Project Manager / Business Development | Event Planning- London Biotechnology Show - Pioneering the Future of Life Sciences - Join us on the Journey of Discovery!
The companies Jixing Pharmaceuticals, Cour Pharmaceuticals, and OnCusp Therapeutics bagged the biggest private biotech investments in January 2024. Around the world, immunology, oncology, and drug discovery players attracted the biggest funding rounds overall. The first month of 2024 saw a lot of initial public offering (IPO) success stories, suggesting a possible recovery for the biotech industry this year. And, although there was not quite as much private biotech financing in January, with 38 rounds in total, a lot of money was still raised by several companies, with the top three investments of the month coming in at $100 million or more. #biotech #healthcare #londonbiotechshow #healthcareinvestment #londonbusiness
The biggest private biotech investments in January 2024
https://www.labiotech.eu
To view or add a comment, sign in
-
Cancer Cachexia Pipeline Analysis Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | AEterna Zentaris, Pfizer, Incyte, Smartfish, Caelus, Helsinn: Delveinsight Business Research LLP As per DelveInsight’s assessment, globally, about 15+ key pharma and biotech companies are working on 15+ pipeline drugs in the Cancer Cachexia therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and … Continue reading → #Finance #FinancialMarket #MarketingSales #PharmaceuticalsBiotech
Cancer Cachexia Pipeline Analysis Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | AEterna Zentaris, Pfizer, Incyte, Smartfish, Caelus, Helsinn
https://www.abnewswire.com/pressreleases
To view or add a comment, sign in
-
Cancer Cachexia Pipeline Analysis Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | AEterna Zentaris, Pfizer, Incyte, Smartfish, Caelus, Helsinn: Delveinsight Business Research LLP As per DelveInsight’s assessment, globally, about 15+ key pharma and biotech companies are working on 15+ pipeline drugs in the Cancer Cachexia therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and … Continue reading → #Finance #FinancialMarket #MarketingSales #PharmaceuticalsBiotech
Cancer Cachexia Pipeline Analysis Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | AEterna Zentaris, Pfizer, Incyte, Smartfish, Caelus, Helsinn
https://www.abnewswire.com/pressreleases
To view or add a comment, sign in
-
IDT Australia Investor Update Unlock the future of pharmaceutical innovation with our exclusive chat featuring Paul McDonald, CEO of IDT Australia Limited Australia. Ever wondered how a company can navigate through a dynamic market while harnessing groundbreaking technologies? Paul divulges IDT's ambitious growth plans, recent capital raise, and the critical role of their new ADC manufacturing facility. Discover the strategic impact of a non-binding takeover offer from MyndBio, a rising star in the psychedelics industry, and what it means for IDT's future. Listen in to understand the revolutionary potential of antibody drug conjugates in targeted cancer therapy and the promising market expansion on the horizon. #biotech #mRNA #AntibodyDrugConjugate #IDTAustralia
IDT AUSTRALIA (IDT) - Unlocking the Future of Pharma: IDT Australia's Paul McDonald on ADC Innovations, Capital Raise, and Strategic Takeover Offers
https://spotify.com
To view or add a comment, sign in
-
"Platform partnering sustains oncology dealmaking" by Mike Ward explores the crucial role of platform partnering in the context of oncology dealmaking. It highlights how collaborations between biotech companies and pharmaceutical firms are vital for advancing oncology treatments and bringing them to market effectively. Key Points: - Platform partnering fuels oncology dealmaking by combining resources and expertise. - Biotech firms specializing in process development and GMP production, support drug development. - Biotech partners offer comprehensive solutions, including small molecules and conjugates. - Analytical capabilities are crucial for ensuring drug quality and control. - Strong biotech-pharma partnerships drive innovation in oncology treatments. KSB specializes in process development and GMP production for high-barrier molecules, including antibody-drug conjugates, peptide-drug conjugates, oligonucleotides, and lipid nanoparticles, offering a total solution throughout the clients' product lifecycle. Our comprehensive analytical capabilities further support all stages of drug process development, ensuring quality and compliance, making KSB a valuable partner for oncology dealmaking. https://lnkd.in/gMxW4iME Article link: https://lnkd.in/gYu4sfRn #CDMO #ADC #oncology #DrugDevelopment
To view or add a comment, sign in
-
Co-Founder @ BiopharmIQ - Helping biotech sales teams get more leads each quarter by reaching their ideal prospects utilizing data. Biopharma data for BD and investors.
Keep a finger on the pulse 🩺 BiopharmIQ will share weekly updates on recent + YTD M&A activity.. If you want access to the historical M&A data reach out: - Disease areas of acq'd - Stage lead asset of acq'd - Tech/modality of acq'd company
🤝 𝐌&𝐀𝐬 𝐚𝐧𝐧𝐨𝐮𝐧𝐜𝐞𝐝 𝐘𝐓𝐃 𝐢𝐧 2024 🤝 M&A highlights from last week…👇 𝐘𝐓𝐃 𝐒𝐮𝐦𝐦𝐚𝐫𝐲: Number Announced: 28 Q1 2024 # Announced: 18 Q2 2024 # Announced: 10 Mariana Zamir MD Acquired By: Novartis Announcement Date: May 2, 2024 Acquisition Price: $1B upfront + up to $750M milestone payment Acquisition Date (Closed): Pending Lead Asset: MC-339 Lead Asset Stage: Preclinical Indication: Small Cell Lung Cancers Epygenix Therapeutics, Inc. Acquired By: Harmony Biosciences Announcement Date: April 30, 2024 Acquisition Price: $35M upfront + up to $130M milestone payment Acquisition Date (Closed): Pending Lead Asset: EPX-100 Lead Asset Stage: Phase 2 Lead Asset Indication: Dravet Syndrome Deciphera Pharmaceuticals Acquired By: ONO Pharmaceuticals Announcement Date: April 29, 2024 Acquisition Price: $2.4B Acquisition Date (Closed): Pending Lead Asset: Ripretinib Lead Asset Stage: Approved Lead Asset Indication: Gastrointestinal stromal tumor -- At BiopharmIQ by Amp we maintain biopharma data to help with your sales/BD activities. 📰 Each week we share clinical/regulatory/funding news in an easy-to-digest format. #biotech #biopharma
To view or add a comment, sign in
-
Pharma and Biotech updates this week 🧬 Here's the latest from the industry: GSK has entered into a $1.4 billion agreement with Aiolos Bio to acquire its Asthma pipeline. Calypso Biotech a company with a pipeline targeting autoimmune diseases has entered an agreement to be acquired by Novartis, in a deal worth up to $425 million. Johnson & Johnson will pay $2 billion to acquire Ambrx, a biotech company, and its pipeline of targeted drugs for cancer. Emergent BioSolutions has won a US government contract of up to $235 million for its anthrax vaccine. Merck acquires Harpoon Therapeutics for $680 million, also strengthening its cancer pipeline. --- I'm Raphael Clements, founder of Clements Partners. I share weekly updates and the latest changes in the Pharma and Biotech industry 🗞️ #pharma #biotech #biopharma
To view or add a comment, sign in
-
ESMO 2023 saw an estimated 33,00 people come together to discuss the latest developments, research findings and treatment strategies in the field of cancer, with pharma companies using the platform for major announcements and clinical trial results. Analysis by Commetric examines the major news drivers behind ESMO 2023, details the emerging narratives from the conference and ranks the most influential organisations taking part. While AstraZeneca held a notable presence, the limelight was dominated by news of disappointing trial results for their experimental precision drug, datopotamab. Merck Group's multi-billion dollar collaboration with Daiichi Sankyo, Inc. to develop antibody-drug conjugates (ADCs) secured a prominent position for the company throughout the conference. For a comprehensive overview, please do click the link to access the complete report! https://lnkd.in/eJ2sXFSm #ESMO2023 #OncologyConference #MedicalInnovations Johnson & Johnson Roche Bristol Myers Squibb Eli Lilly and Company Pfizer Amgen Genentech Bayer Gilead Sciences GSK Eisai Co., Ltd. Astellas Pharma Exelixis Sanofi Boehringer Ingelheim BioNTech SE AbbVie
To view or add a comment, sign in
-
-
Senior Technical Recruiter (Biotech) // PD, MSAT, Tech Transfer, Manufacturing, CMC (USP/DSP/DP) | Actively recruiting for Senior Roles in Switzerland
The ADC space has more competition now. Samsung Biologics has recently announced a collaborative venture with LegoChem Biosciences for the development and production of Antibody-Drug Conjugates (ADCs). Samsung Biologics' proficiency in biopharmaceutical manufacturing will go hand in hand with LegoChem Biosciences' innovative ADC technology platform. ADCs represent a promising therapeutic approach in cancer treatment by targeting cancer cells specifically, thus minimizing harm to healthy tissues (see Lonza from my previous article). Samsung Biologics will provide its advanced manufacturing facilities and extensive experience in biologics production, while LegoChem Biosciences will contribute its proprietary ConjuAll platform, enabling precise control over the drug-antibody ratio (DAR) critical for optimizing the effectiveness and safety of ADCs. This collaboration will improve Samsung Biologics' commitment to the biopharmaceutical industry, particularly in the oncology sector. The partnership represents a strategic synergy, leveraging the respective strengths of Samsung Biologics and LegoChem Biosciences to advance the field of ADCs and introduce novel treatment options for individuals battling cancer. Source: https://lnkd.in/ehgVV37p #Biopharmaceuticals #CancerResearch #ADCDevelopment #InnovationInOncology #BiotechPartnership #OncologyTherapies
To view or add a comment, sign in
-